Gilvocarcins, new antitumor antibiotics. 3. Antitumor activity.
Gilvocarcin V, isolated rom a Streptomyces culture showed activity against experimental tumors such as sarcoma 180, Ehrlich carcinoma, Meth 1 fibrosarcoma, MH134 hepatoma and lymphocytic leukemia P388. In particular, 40% of treated mice survived for 60 days, after intraperitoneal administration of gilvocarcin V to mice bearing Ehrlich  ascites carcinoma. But it was marginally active against B16 melanoma and did not produce prolongation of lifespan of mice bearing Lewis lung carcinoma.
D000617:Aminoglycosides; D000818:Animals; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D003374:Coumarins; D006027:Glycosides / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D007928:Lethal Dose 50; D007962:Leukocytes / Q000187:drug effects; D008297:Male; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D009374:Neoplasms, Experimental / Q000097:blood / Q000188:drug therapy / Q000401:mortality
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D003374:Coumarins; D006027:Glycosides; D008937:Mitomycins; D016685:Mitomycin; C031782:gilvocarcin M; C031781:gilvocarcin V